MARK2 and ameloblastoma: The systematic review by González-González et al. [99] on B-Raf proto-oncogene serine and threonine kinase V600E mutation for ameloblastoma-targeted patients’ treatments summarizes that when surgical treatments for ameloblastomas are not an option, the discovery of these genomic biomarkers has revolutionized alternative therapies.